All In Biotech

Drug Trial Radar · NCT00537394

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

The Optimized Treatment That Includes or Omits NRTIs Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen

Last checked: Nov 20, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

Jan 2008

Primary completion

May 2012

Study completion Apr 2013

Sponsor

Sponsor type
NIH
Collaborators
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
First posted
Oct 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of anti-HIV therapy is to prevent HIV from replicating. Long-term control of HIV requires at least two anti-HIV drugs that are active against the virus. Drug resistance is a problem for many treatment-experienced, HIV-infected people. The purpose of this study was to determine the benefit of adding a nucleoside reverse transcriptase inhibitor (NRTI) to a new anti-HIV drug regimen for the suppression of HIV.

Conditions

  • HIV Infections

Interventions

  • EnfuvirtideDrug

    90mg subcutaneously twice daily

  • RaltegravirDrug

    400 mg twice daily

  • DarunavirDrug

    Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

  • TipranavirDrug

    Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)

  • EtravirineDrug

    Two 100-mg tablets twice daily

  • MaravirocDrug

    Dosage dependent on regimen in which maraviroc is included

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants With Regimen Failure, Defined as a Confirmed Virologic Failure or Discontinuation of Randomized NRTI Component of Study TreatmentTime frame: From study entry to end of Week 48 evaluation window

Locations

64 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama Therapeutics CRS

    Birmingham, Alabama

  • Miller Children's Hosp. Long Beach CA NICHD CRS

    Long Beach, California

  • University of Southern California CRS

    Los Angeles, California

  • Usc La Nichd Crs

    Los Angeles, California

  • UCLA CARE Center CRS

    Los Angeles, California

  • UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS

    Los Angeles, California

  • Stanford AIDS Clinical Trials Unit CRS

    Palo Alto, California

  • UCSD Antiviral Research Center CRS

    San Diego, California

  • Ucsf Hiv/Aids Crs

    San Francisco, California

  • Univ. of California San Francisco NICHD CRS

    San Francisco, California

  • University of Colorado Hospital CRS

    Aurora, Colorado

  • Denver Public Health CRS

    Denver, Colorado

  • Georgetown University CRS (GU CRS)

    Washington D.C., District of Columbia

  • Children's National Med. Ctr. ATN CRS

    Washington D.C., District of Columbia

  • Howard Univ. Washington DC NICHD CRS

    Washington D.C., District of Columbia

  • Pediatric Perinatal HIV Clinical Trials Unit CRS

    Miami, Florida

  • The Ponce de Leon Center CRS

    Atlanta, Georgia

  • Northwestern University CRS

    Chicago, Illinois

  • Rush University CRS

    Chicago, Illinois

  • Tulane Univ. New Orleans NICHD CRS

    New Orleans, Louisiana

  • IHV Baltimore Treatment CRS

    Baltimore, Maryland

  • Johns Hopkins University CRS

    Baltimore, Maryland

  • Massachusetts General Hospital CRS (MGH CRS)

    Boston, Massachusetts

  • Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS

    Boston, Massachusetts

  • Bmc Actg Crs

    Boston, Massachusetts

  • Boston Medical Center Ped. HIV Program NICHD CRS

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS

    Boston, Massachusetts

  • Wayne State Univ. CRS

    Detroit, Michigan

  • Henry Ford Hosp. CRS

    Detroit, Michigan

  • Washington University Therapeutics (WT) CRS

    St Louis, Missouri

  • Cooper Univ. Hosp. CRS

    Camden, New Jersey

  • New Jersey Medical School Clinical Research Center CRS

    Newark, New Jersey

  • Rutgers - New Jersey Medical School CRS

    Newark, New Jersey

  • Weill Cornell Chelsea CRS

    New York, New York

  • NY Univ. HIV/AIDS CRS

    New York, New York

  • Nyu Ny Nichd Crs

    New York, New York

  • Metropolitan Hosp. NICHD CRS

    New York, New York

  • Columbia P&S CRS

    New York, New York

  • Columbia IMPAACT CRS

    New York, New York

  • Harlem ACTG CRS

    New York, New York

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.